Drug Profile
Anti-GD2 chimeric antigen receptor T cell therapy - Sinobioway Cell Therapy
Alternative Names: CAR-GD2-modified T cells - Sinobioway Cell Therapy; GD2-specific Chimeric Antigen Receptor-modified T Cells - Sinobioway Cell Therapy; GD2-targeted CAR-T cells - Sinobioway Cell TherapyLatest Information Update: 23 Feb 2022
Price :
$50
*
At a glance
- Originator Sinobioway Cell Therapy
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuroblastoma
Most Recent Events
- 23 Feb 2022 No development reported - Phase-I/II for Neuroblastoma (In adolescents, In children, In infants, Second-line therapy or greater) in China (Parenteral)
- 01 Sep 2016 Phase-I/II clinical trials in Neuroblastoma (Second-line therapy or greater, In children, In infants, In adolescents) in China (Parenteral) (NCT02919046)